2020
Uptake of first-line immune checkpoint inhibitors among medically frail patients with advanced solid malignancies.
Parikh R, Cohen R, Min E, Wileyto E, Riaz F, Gross C, Long Q, Mamtani R. Uptake of first-line immune checkpoint inhibitors among medically frail patients with advanced solid malignancies. Journal Of Clinical Oncology 2020, 38: e19316-e19316. DOI: 10.1200/jco.2020.38.15_suppl.e19316.Peer-Reviewed Original ResearchNon-small cell lung cancerAdvanced solid malignanciesEastern Cooperative Oncology Group performance statusUrothelial cell carcinomaRenal cell carcinomaNon-frail patientsFrail patientsSolid malignanciesHepatocellular carcinomaCell carcinomaFlatiron Health electronic health record-derived databaseStage IV non-small cell lung cancerElectronic health record-derived databaseFirst-line immune checkpoint inhibitorsFirst-line ICI treatmentFirst-line systemic therapyImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyImmune checkpoint inhibitorsRetrospective cohort studyFirst-line useElixhauser Comorbidity IndexCell lung cancerMultivariable logistic regressionYears of treatment
2012
Predictors of early discontinuation of chemotherapy (EDC) in patients (pts) age 65 or older with stage IV non-small cell lung cancer (NSCLC).
Gajra A, Tew W, Hardt M, Mohile S, Owusu C, Klepin H, Gross C, Lichtman S, Katheria V, Hurria A. Predictors of early discontinuation of chemotherapy (EDC) in patients (pts) age 65 or older with stage IV non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2012, 30: e18133-e18133. DOI: 10.1200/jco.2012.30.15_suppl.e18133.Peer-Reviewed Original ResearchStage IV non-small cell lung cancerNon-small cell lung cancerPoor physical functionOlder ptsPhysical functionAge 65Multi-site prospective studyBivariate analysisGeriatric assessment variablesPatients age 65Cell lung cancerMultivariate logistic regressionLower mean HbPt ageChemotherapy toxicityEarly discontinuationAlbumin levelsMean HbProspective studyPoor outcomeHigher cancerLung cancerPhysical scoresSubset analysisDisease progression